Your browser doesn't support javascript.
loading
Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia.
Waanders, Esmé; Gu, Zhaohui; Dobson, Stephanie M; Antic, Zeljko; Crawford, Jeremy Chase; Ma, Xiaotu; Edmonson, Michael N; Payne-Turner, Debbie; van de Vorst, Maartje; Jongmans, Marjolijn C J; McGuire, Irina; Zhou, Xin; Wang, Jian; Shi, Lei; Pounds, Stanley; Pei, Deqing; Cheng, Cheng; Song, Guangchun; Fan, Yiping; Shao, Ying; Rusch, Michael; McCastlain, Kelly; Yu, Jiangyan; van Boxtel, Ruben; Blokzijl, Francis; Iacobucci, Ilaria; Roberts, Kathryn G; Wen, Ji; Wu, Gang; Ma, Jing; Easton, John; Neale, Geoffrey; Olsen, Scott R; Nichols, Kim E; Pui, Ching-Hon; Zhang, Jinghui; Evans, William E; Relling, Mary V; Yang, Jun J; Thomas, Paul G; Dick, John E; Kuiper, Roland P; Mullighan, Charles G.
Afiliação
  • Waanders E; Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Gu Z; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Dobson SM; Department of Genetics, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Antic Z; Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Crawford JC; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Ma X; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Edmonson MN; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Payne-Turner D; Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • van de Vorst M; Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Jongmans MCJ; Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • McGuire I; Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Zhou X; Department of Human Genetics, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands.
  • Wang J; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Shi L; Department of Genetics, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Pounds S; Department of Information Services, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Pei D; Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Cheng C; Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Song G; Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Fan Y; Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Shao Y; Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Rusch M; Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • McCastlain K; Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Yu J; Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • van Boxtel R; Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Blokzijl F; Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Iacobucci I; Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Roberts KG; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Wen J; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Wu G; Oncode Institute, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Ma J; Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Easton J; Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Neale G; Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Olsen SR; Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Nichols KE; Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Pui CH; Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Zhang J; Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Evans WE; The Hartwell Center for Bioinformatics and Biotechnology, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Relling MV; The Hartwell Center for Bioinformatics and Biotechnology, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Yang JJ; Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Thomas PG; Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Dick JE; Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Kuiper RP; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Mullighan CG; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
Blood Cancer Discov ; 1(1): 96-111, 2020 07.
Article em En | MEDLINE | ID: mdl-32793890
ABSTRACT
Relapse of acute lymphoblastic leukemia (ALL) remains a leading cause of childhood death. Prior studies have shown clonal mutations at relapse often arise from relapse-fated subclones that exist at diagnosis. However, the genomic landscape, evolutionary trajectories and mutational mechanisms driving relapse are incompletely understood. In an analysis of 92 cases of relapsed childhood ALL, incorporating multimodal DNA and RNA sequencing, deep digital mutational tracking and xenografting to formally define clonal structure, we identify 50 significant targets of mutation with distinct patterns of mutational acquisition or enrichment. CREBBP, NOTCH1, and Ras signaling mutations rose from diagnosis subclones, whereas variants in NCOR2, USH2A and NT5C2 were exclusively observed at relapse. Evolutionary modeling and xenografting demonstrated that relapse-fated clones were minor (50%), major (27%) or multiclonal (18%) at diagnosis. Putative second leukemias, including those with lineage shift, were shown to most commonly represent relapse from an ancestral clone rather than a truly independent second primary leukemia. A subset of leukemias prone to repeated relapse exhibited hypermutation driven by at least three distinct mutational processes, resulting in heightened neoepitope burden and potential vulnerability to immunotherapy. Finally, relapse-driving sequence mutations were detected prior to relapse using deep digital PCR at levels comparable to orthogonal approaches to monitor levels of measurable residual disease. These results provide a genomic framework to anticipate and circumvent relapse by earlier detection and targeting of relapse-fated clones.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras / Evolução Clonal Limite: Child / Humans Idioma: En Revista: Blood Cancer Discov Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras / Evolução Clonal Limite: Child / Humans Idioma: En Revista: Blood Cancer Discov Ano de publicação: 2020 Tipo de documento: Article